Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 10/2017 | Visterra | Series C | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 7/2021 | IgGenix | Series A | 0 |
| 3/2022 | Creyon Bio | Series A | 0 |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2018 | QurAlis | Seed Round | - |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 5/2021 | Marvin | Seed Round | 0 |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 5/2021 | miRecule | Venture Round | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 12/2022 | Dantari | Series A | 0 |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 12/2020 | RayzeBio | Series B | 105M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 2/2018 | Kallyope | Series B | 66M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 6/2022 | Dren Bio | Series B | 0 |
| 1/2022 | Avalo | Convertible Note | 750k |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 1/2021 | Encodia | Series C | 75M |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 8/2021 | Humacyte | PIPE | 175M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 4/2023 | Function Oncology | Series A | 28M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 3/2019 | Gencove | Seed Round | 3M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
